Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: A randomized clinical trial

JAMA

Volumn 311, Issue 24, 2014, Pages 2490-2498

  Van Laar, Jacob M ^a   Farge, Dominique ^b   Sont, Jacob K ^c   Naraghi, Kamran ^d   Marjanovic, Zora ^e   Larghero, Jérôme ^b   Schuerwegh, Annemie J ^c   Marijt, Erik W A ^c   Vonk, Madelon C ^f   Schattenberg, Anton V ^f   Matucci Cerinic, Marco ^g   Voskuyl, Alexandre E ^h   Van De Loosdrecht, Arjan A ^h   Daikeler, Thomas ⁱ   Kötter, Ina ^j   Schmalzing, Marc ^j   Martin, Thierry ^k   Lioure, Bruno ^l   Weiner, Stefan M ^m   Kreuter, Alexander ⁿ   Deligny, Christophe ^o   Durand, Jean Marc ^p   Emery, Paul ^q   Machold, Klaus P ^r   Sarrot Reynauld, Francoise ^s   Warnatz, Klaus ^t   Adoue, Daniel F P ^u   Constans, Joël ^v   Tony, Hans Peter ^w   Del Papa, Nicoletta ^x   Fassas, Athanasios ^y   Himsel, Andrea ^z   Launay, David ^aa   Lo Monaco, Andrea ^ab   Philippe, Pierre ^ac   Queŕé, Isabelle ^ad   Rich, Eŕic ^ae   Westhovens, Rene ^af   Griffiths, Bridget ^ag   Saccardi, Riccardo ^ah   Van Den Hoogen, Frank H ^ai   Fibbe, Willem E ^c   Socié, Geŕard ^b   Gratwohl, Alois ⁱ   Tyndall, Alan ⁱ   more..

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b SAINT LOUIS HOSPITAL   (France)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d Ames Cook University Hospital   (United Kingdom)

^e HÔPITAL SAINT ANTOINE   (France)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^g UNIVERSITY OF FLORENCE   (Italy)

^h VU UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ UNIVERSITY HOSPITAL BASEL   (Switzerland)

^j UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^k UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^l HÔPITAL DE HAUTEPIERRE   (France)

^m KRANKENHAUS DER BARMHERZIGEN BRÜDER   (Germany)

ⁿ St Elisabeth Hospital   (Germany)

^o CENTRE HOSPITALIER UNIVERSITAIRE DE FORT DE FRANCE   (France)

^p HÔPITAL DE LA CONCEPTION   (France)

^q UNIVERSITY OF LEEDS   (United Kingdom)

^r MEDICAL UNIVERSITY OF VIENNA   (Austria)

^s GRENOBLE UNIVERSITY HOSPITAL   (France)

^t UNIVERSITY OF FREIBURG   (Germany)

^u TOULOUSE UNIVERSITY HOSPITAL   (France)

^v HÔPITAL SAINT ANDRÉ   (France)

^w UNIVERSITY OF WÜRZBURG   (Germany)

^x ISTITUTO ORTOPEDICO GAETANO PINI   (Italy)

^y G PAPANICOLAOU HOSPITAL   (Greece)

^z UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^aa LILLE UNIVERSITY HOSPITAL   (France)

^ab UNIVERSITY OF FERRARA   (Italy)

^ac UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^ad MONTPELLIER UNIVERSITY HOSPITAL   (France)

^ae CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^af UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^ag FREEMAN HOSPITAL   (United Kingdom)

^ah CAREGGI UNIVERSITY HOSPITAL   (Italy)

^ai SINT MAARTENSKLINIEK   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CAUSE OF DEATH; CLINICAL EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; EPSTEIN BARR VIRUS INFECTION; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HEPATITIS B; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; INTERMETHOD COMPARISON; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SENSITIVITY ANALYSIS; SURVIVAL RATE; SYSTEMIC SCLEROSIS; VIRUS INFECTION; YOUNG ADULT;

ADULT; AUTOGRAFTS; CYCLOPHOSPHAMIDE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; SCLERODERMA, DIFFUSE; SURVIVAL ANALYSIS;

EID: 84902844800     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2014.6368     Document Type: Article

References (26)

1. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med. 2009;360(19):1989-2003.
2. Chifflot H, Fautrel B, Sordet C, Chatelus E, Sibilia J. Incidence and prevalence of systemic sclerosis. Semin Arthritis Rheum. 2008;37(4):223-235.
3. Tyndall A, Black C, Finke J, et al. Treatment of systemic sclerosis with autologous haemopoietic stem cell transplantation. Lancet. 1997;349(9047):254. (Pubitemid 27050998)
4. Binks M, Passweg JR, Furst D, et al. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease. Ann Rheum Dis. 2001;60(6):577-584. (Pubitemid 32493984)
5. Farge D, Passweg J, van Laar JM, et al EBMT/EULAR Registry. Autologous stem cell transplantation in the treatment of systemic sclerosis. Ann Rheum Dis. 2004;63(8):974-981. (Pubitemid 38961924)
6. Nash RA, McSweeney PA, Crofford LJ, et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis. Blood. 2007;110(4):1388-1396. (Pubitemid 47281441)
7. Vonk MC, Marjanovic Z, van den Hoogen FH, et al. Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis. Ann Rheum Dis. 2008;67(1):98-104.
8. Burt RK, Shah SJ, Dill K, et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST). Lancet. 2011;378(9790):498-506.
9. Burt RK, Oliveira MC, Shah SJ, et al. Cardiac involvement and treatment-related mortality after non-myeloablative haemopoietic stem-cell transplantation with unselected autologous peripheral blood for patients with systemic sclerosis. Lancet. 2013;381(9872):1116-1124.
10. Fleming JN, Nash RA, McLeod DO, et al. Capillary regeneration in scleroderma: stem cell therapy reverses phenotype? [published correction appears in PLoS One. 2008;3(8)]. PLoS One. 2008;3(1):e1452.
11. Launay D, Marjanovic Z, de Bazelaire C, et al. Autologous hematopoietic stem cell transplant in systemic sclerosis: quantitative high resolution computed tomography of the chest scoring. J Rheumatol. 2009;36(7):1460-1463.
12. Verrecchia F, Laboureau J, Verola O, et al. Skin involvement in scleroderma. Rheumatology (Oxford). 2007;46(5):833-841.
13. Farge D, Henegar C, Carmagnat M, et al. Analysis of immune reconstitution after autologous bone marrow transplantation in systemic sclerosis. Arthritis Rheum. 2005;52(5):1555-1563. (Pubitemid 40663947)
14. Saccardi R, Tyndall A, Coghlan G, et al. Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis. Bone Marrow Transplant. 2004;34(10):877-881. (Pubitemid 39562137)
15. Tyndall A, Gratwohl A. Blood and marrow stem cell transplants in auto-immune disease: a consensus report written on behalf of the European League Against Rheumatism (EULAR) and the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 1997;19(7):643-645. (Pubitemid 27182485)
16. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980;23(5):581-590.
17. Khanna D, Furst DE, Hays RD, et al. Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study. Ann Rheum Dis. 2006;65(10):1325-1329. (Pubitemid 44620441)
18. Hudson M, Lo E, Lu Y, Hercz D, Baron M, Steele R. Cigarette smoking in patients with systemic sclerosis. Arthritis Rheum. 2011;63(1):230-238.
19. Tran BT, Halperin A, Chien JW. Cigarette smoking and outcomes after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2011;17(7):1004-1011.
20. Ehlers SL, Gastineau DA, Patten CA, et al. The impact of smoking on outcomes among patients undergoing hematopoietic SCT for the treatment of acute leukemia. Bone Marrow Transplant. 2011;46(2):285-290.
21. Pasquini MC, Voltarelli J, Atkins HL, et al. Transplantation for autoimmune diseases in north and South America: a report of the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2012;18(10):1471-1478.
22. Farge D, Labopin M, Tyndall A, et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases. Haematologica. 2010;95(2):284-292.
23. Fox BD, Shimony A, Langleben D, et al. High prevalence of occult left heart disease in scleroderma-pulmonary hypertension. Eur Respir J. 2013;42(4):1083-1091.
24. Snowden JA, Saccardi R, Allez M, et al EBMT Autoimmune Disease Working Party (ADWP); Paediatric Diseases Working Party (PDWP). Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2012;47(6):770-790.
25. Fransen J, Popa-Diaconu D, Hesselstrand R, et al. Clinical prediction of 5-year survival in systemic sclerosis: validation of a simple prognostic model in EUSTAR centres. Ann Rheum Dis. 2011;70(10):1788-1792.
26. Domsic RT, Rodriguez-Reyna T, Lucas M, Fertig N, Medsger TA Jr. Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma [published correction appears in Ann Rheum Dis. 2011;70(7):1350]. Ann Rheum Dis. 2011;70(1):104-109.